| Title： | Chinese expert consensus on the use of Sirolimus in systemic lupus erythematosus |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Treatment |
| Countries and regions： | China |
| Guidelines users： | Rheumatology immunologists, nephrologists, clinical pharmacists and professionals involved in the diagnosis, treatment and management of systemic lupus erythematosus |
| Evidence classification method： | Oxford Center for Evidence⁃ Based Medicine（OCEBM）2011 Levels of Evidence |
| Development unit： | National Clinical Medical Research Center for Skin and Immune Diseases (NCRC), Rheumatology and Immunology Branch of Chinese Medical Doctor Association |
| Registration time: | 2024-07-23 |
| Registration number： | PREPARE-2024CN044 |
| Purpose of the guideline: | Systemic lupus erythematosus is an autoimmune disease involving multiple organs and systems. The standardized mortality rate of SLE in traditional treatment is still significantly higher than that of the general population, with many clinical problems such as low remission rate, high recurrence rate, and organ damage caused by adverse drug reactions. In recent years, more and more clinical studies have found that mTORi can effectively reduce disease activity and hormone dosage in the treatment of SLE, and is relatively safe with no serious adverse events reported. In order to provide a better reference for the application of sirolimus in the treatment of systemic lupus erythematosus, the National Clinical Medical Research Center for Skin and Immune Diseases and the Rheumatology and Immunology Branch of the Chinese Medical Doctor Association organized experienced domestic experts in related fields, combined with published domestic and foreign research progress, and jointly formulated this expert consensus after extensive consultation. |
Latest registration
